Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.011
A. Sharma, Nikhil Sharma, Tanya, Jaiprakash Verma, Ankur
The finest foods for bodybuilding, or "Superfoods," in our everyday diet are fruits. And now is the moment to join the movement for a successful year to come. They aid in muscular growth and are tasty and healthful. Yes, it is. Fruits are sometimes disregarded in bodybuilding communities because of their sugar content, but with good planning, gains may be increased.Fruits are a good source of potassium, carbohydrates, vitamin C, and antioxidants, all of which aid in muscle growth. The very best Fruits won't empty your bank account. These affordable natural supplements provide a balanced intake of vitamins, minerals, and nutrients without the unintended negative effects of synthetic supplements.Fiber might be beneficial if you're trying to gain strength and muscle. It doesn't directly fuel your gains or induce muscular growth, but it does other things that can improve your workout performance.
{"title":"Fibers as nutraceuticals: A review","authors":"A. Sharma, Nikhil Sharma, Tanya, Jaiprakash Verma, Ankur","doi":"10.18231/j.jpbs.2022.011","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.011","url":null,"abstract":"The finest foods for bodybuilding, or \"Superfoods,\" in our everyday diet are fruits. And now is the moment to join the movement for a successful year to come. They aid in muscular growth and are tasty and healthful. Yes, it is. Fruits are sometimes disregarded in bodybuilding communities because of their sugar content, but with good planning, gains may be increased.Fruits are a good source of potassium, carbohydrates, vitamin C, and antioxidants, all of which aid in muscle growth. The very best Fruits won't empty your bank account. These affordable natural supplements provide a balanced intake of vitamins, minerals, and nutrients without the unintended negative effects of synthetic supplements.Fiber might be beneficial if you're trying to gain strength and muscle. It doesn't directly fuel your gains or induce muscular growth, but it does other things that can improve your workout performance.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73190241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.016
Sheetal Sheetal Mane, M. Khan
A simple, accurate, precise, cost effective, rapid and sensitive UV/visible spectrophotometric method was developed for the determination of Vildagliptin in active pharmaceutical dosage form. The developed method was validated as per ICH guidelines.The purity of Vildagliptin was characterized by melting point, Fourier Transform Infra-Red and DSC. The drug was analyzed using UV/visible spectrophotometric method was validated in terms of linearity and range. The solvents used was water, 0.1 N HCl and phosphate buffer pH 7.4 and the wavelength corresponding to maximum absorbance of the drug were found at 210 nm.Melting point of drug was found 151.67°C nearly corresponds to its actual melting range. The linear response for concentration range of 2-12 µg/ml of vildagliptin for water, 0.1 N HCl and phosphate buffer pH 7.4 was recorded each with regression coefficient R = 0.9998, 0.9994 and 0.9991 respectively.The drug was confirmed by interpretation of UV spectra. Hence, proposed method stands out validated and shows a linear relationship and thus may be used for routine analysis of Vildagliptin in pharmaceutical dosage forms.
建立了一种简便、准确、精密度高、成本效益好、快速灵敏的紫外/可见分光光度法测定活性制剂维格列汀含量的方法。所开发的方法按照ICH指南进行了验证。用熔点、傅里叶变换红外光谱和差示量热分析对维格列汀的纯度进行了表征。采用紫外/可见分光光度法对药物进行分析，并在线性和范围上进行了验证。溶剂为水、0.1 N HCl和pH 7.4的磷酸盐缓冲液，药物最大吸光度对应的波长为210 nm。熔点151.67℃与药物的实际熔点基本一致。维格列汀在2 ~ 12µg/ml的浓度范围内对水、0.1 N HCl和pH 7.4的磷酸盐缓冲液均有线性响应，回归系数R分别为0.9998、0.9994和0.9991。通过紫外光谱分析证实了该药物的药性。因此，所提出的方法经过验证并显示出线性关系，因此可用于药物剂型中维格列汀的常规分析。
{"title":"Development of UV-Visible spectrophotometric method for the estimation of vildagliptin in different medium","authors":"Sheetal Sheetal Mane, M. Khan","doi":"10.18231/j.jpbs.2022.016","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.016","url":null,"abstract":"A simple, accurate, precise, cost effective, rapid and sensitive UV/visible spectrophotometric method was developed for the determination of Vildagliptin in active pharmaceutical dosage form. The developed method was validated as per ICH guidelines.The purity of Vildagliptin was characterized by melting point, Fourier Transform Infra-Red and DSC. The drug was analyzed using UV/visible spectrophotometric method was validated in terms of linearity and range. The solvents used was water, 0.1 N HCl and phosphate buffer pH 7.4 and the wavelength corresponding to maximum absorbance of the drug were found at 210 nm.Melting point of drug was found 151.67°C nearly corresponds to its actual melting range. The linear response for concentration range of 2-12 µg/ml of vildagliptin for water, 0.1 N HCl and phosphate buffer pH 7.4 was recorded each with regression coefficient R = 0.9998, 0.9994 and 0.9991 respectively.The drug was confirmed by interpretation of UV spectra. Hence, proposed method stands out validated and shows a linear relationship and thus may be used for routine analysis of Vildagliptin in pharmaceutical dosage forms.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"102 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79625877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.014
S. Khanam, Sumon Sheel, Poulomi Biswas, Varnita Karmakar
Ethosomes are elastic nanovesicles with phospholipid bases that are noninvasive delivery vehicles and have a high ethanol concentration (20–45%). As transdermal drug delivery confers poor penetration, the major obstacle is the low diffusion rate of drugs across the stratum corneum. The sophisticated ethosomal delivery systems enable drugs to reach the deep skin layers and/or the systemic circulation. The development of these new carriers involves the employment of several preparatory processes. Ethosomal dispersions are added to gels, patches, and creams for ease of use and stability. Ethanol is known as an efficient permeation enhancer and has been added in the vesicular systems to prepare elastic nanovesicles. It has the potential to interact with the polar head group region of lipid molecules, lowering the melting point of the stratum corneum lipid and raising lipid fluidity and cell membrane permeability as a result. Ethosomes' special structure allows them to enclose and transmit through the skin highly lipophilic substances like propranolol and trihexyphenidil as well as cationic medicines like testosterone and minoxidil. This article provides a detailed review of the ethosomal structure, mechanism of penetration along with various methods of preparation. Also, the article focuses on the applications of ethosomal carriers and opportunities for the research and future development of novel improved therapies.
{"title":"Ethosome as a potential transdermal drug delivery system","authors":"S. Khanam, Sumon Sheel, Poulomi Biswas, Varnita Karmakar","doi":"10.18231/j.jpbs.2022.014","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.014","url":null,"abstract":"Ethosomes are elastic nanovesicles with phospholipid bases that are noninvasive delivery vehicles and have a high ethanol concentration (20–45%). As transdermal drug delivery confers poor penetration, the major obstacle is the low diffusion rate of drugs across the stratum corneum. The sophisticated ethosomal delivery systems enable drugs to reach the deep skin layers and/or the systemic circulation. The development of these new carriers involves the employment of several preparatory processes. Ethosomal dispersions are added to gels, patches, and creams for ease of use and stability. Ethanol is known as an efficient permeation enhancer and has been added in the vesicular systems to prepare elastic nanovesicles. It has the potential to interact with the polar head group region of lipid molecules, lowering the melting point of the stratum corneum lipid and raising lipid fluidity and cell membrane permeability as a result. Ethosomes' special structure allows them to enclose and transmit through the skin highly lipophilic substances like propranolol and trihexyphenidil as well as cationic medicines like testosterone and minoxidil. This article provides a detailed review of the ethosomal structure, mechanism of penetration along with various methods of preparation. Also, the article focuses on the applications of ethosomal carriers and opportunities for the research and future development of novel improved therapies.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90359511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.010
Virender Kumar, N. Kumar, Manithu Shilsut, J. Kumar
A nanotechnology can be described as the process of manipulating, studying, and manufacturing objects with a nanometer dimension. Through site-specific, targeted delivery of medicines, nanotechnology can benefit the treatment of chronic diseases in humans. Recent nanomedicine discoveries have led to the development of numerous outstanding drugs e.g., chemotherapeutics, biologics, immunotherapeutic, etc. The purpose of this chapter is to describe various nanocarriers that can be used to deliver therapeutic molecules.
{"title":"Nanotechnology- based target drug delivery system","authors":"Virender Kumar, N. Kumar, Manithu Shilsut, J. Kumar","doi":"10.18231/j.jpbs.2022.010","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.010","url":null,"abstract":"A nanotechnology can be described as the process of manipulating, studying, and manufacturing objects with a nanometer dimension. Through site-specific, targeted delivery of medicines, nanotechnology can benefit the treatment of chronic diseases in humans. Recent nanomedicine discoveries have led to the development of numerous outstanding drugs e.g., chemotherapeutics, biologics, immunotherapeutic, etc. The purpose of this chapter is to describe various nanocarriers that can be used to deliver therapeutic molecules.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80779924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.009
F. Tamboli
{"title":"Phytonanotechnology","authors":"F. Tamboli","doi":"10.18231/j.jpbs.2022.009","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.009","url":null,"abstract":"","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73361841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.013
S. Bhale
A fast, simple, reliable and accurate RPHPLC analytical method was developed for the evaluation of botulinum toxin, and the developed method was subsequently validated according to ICH guidelines in sterile dosage form for stability studies. A C18 column with a flow rate of 2 ml/min was selected. The mobile phase chosen consisted of sodium phosphate buffer (0.05 M) at pH 2.8 and acetonitrile in a ratio of 30:70 respectively at 214 nm. Measured at an Rt of 2.1 min. 10 minutes running time. Linearity and range were observed at concentrations from 1 µg/ml to 10 µg/ml. The method developed was linear with a correlation coefficient of 0.99. Validation of the method was performed according to ICH guidelines for assay, linearity and range, precision, limit of detection, limit of quantitation, and forced degradation test.
{"title":"The ICH guidelines in practices: Stress degradation studies on botulinum toxin and validation of developed stability-indicating HPLC method","authors":"S. Bhale","doi":"10.18231/j.jpbs.2022.013","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.013","url":null,"abstract":"A fast, simple, reliable and accurate RPHPLC analytical method was developed for the evaluation of botulinum toxin, and the developed method was subsequently validated according to ICH guidelines in sterile dosage form for stability studies. A C18 column with a flow rate of 2 ml/min was selected. The mobile phase chosen consisted of sodium phosphate buffer (0.05 M) at pH 2.8 and acetonitrile in a ratio of 30:70 respectively at 214 nm. Measured at an Rt of 2.1 min. 10 minutes running time. Linearity and range were observed at concentrations from 1 µg/ml to 10 µg/ml. The method developed was linear with a correlation coefficient of 0.99. Validation of the method was performed according to ICH guidelines for assay, linearity and range, precision, limit of detection, limit of quantitation, and forced degradation test.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87932688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.017
B. Jyothi, R. Shetty, Mohandas Rai
According to a WHO report, approximately 55 million people in India are still living in poverty as a result of household out-of-pocket expenses for health care, particularly medications. Thus, it is imperative to keep healthcare costs as low as possible without limiting access to high-quality care. Increasing the use of generic medications can raise affordability of healthcare without sacrificing the standard of care. Doctors' prescriptions play an extremely significant role. In order to identify potential obstacles to the use of generic drugs, it may be helpful to understand the doctor's perspective about generic drugs.A cross-sectional study was carried out using a validated questionnaire that included questions to evaluate the participant’s knowledge and attitude on generic medicines. Data was collected using google forms and Chi square test was used to list association of knowledge and attitude.It was observed that attitude among interns were extremely significant whereas the knowledge was insignificant.According to the study, knowledge about generic drugs were not significant however they had significant attitude towards it so educating interns and medical students about generic drugs will promote more awareness about prescribing generic medicine.
{"title":"A study on assessment of knowledge and attitude about generic medicines among interns in a tertiary care hospital","authors":"B. Jyothi, R. Shetty, Mohandas Rai","doi":"10.18231/j.jpbs.2022.017","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.017","url":null,"abstract":"According to a WHO report, approximately 55 million people in India are still living in poverty as a result of household out-of-pocket expenses for health care, particularly medications. Thus, it is imperative to keep healthcare costs as low as possible without limiting access to high-quality care. Increasing the use of generic medications can raise affordability of healthcare without sacrificing the standard of care. Doctors' prescriptions play an extremely significant role. In order to identify potential obstacles to the use of generic drugs, it may be helpful to understand the doctor's perspective about generic drugs.A cross-sectional study was carried out using a validated questionnaire that included questions to evaluate the participant’s knowledge and attitude on generic medicines. Data was collected using google forms and Chi square test was used to list association of knowledge and attitude.It was observed that attitude among interns were extremely significant whereas the knowledge was insignificant.According to the study, knowledge about generic drugs were not significant however they had significant attitude towards it so educating interns and medical students about generic drugs will promote more awareness about prescribing generic medicine.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90345815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-15DOI: 10.18231/j.jpbs.2022.004
S. Chaudhry
The past 15 years have seen increased usage of factor Xa inhibitor anticoagulants such as rivaroxaban, apixaban, and edoxaban, along with dabigatran (competitive direct thrombin inhibitor), which have been used increasingly in various clinical settings, for the prevention and treatment of thrombosis. In many ways Factor Xa inhibitors have replaced the use of warfarin, which requires prudent monitoring . Factor Xa inhibitor short half-lives, compared to warfarin’s, provide some assurance that the drug concentrations will decline rapidly when therapy is discontinued in patients with normal renal function. Good haemostatic efficacy was achieved in 83% patients on apixaban and 80% patients on rivaroxaban . Major bleeding events in nonvalvular atrial fibrillation patients on rivaroxaban were 3.6% per year and on apixaban were 2.13% per year in respective landmark trials conducted. Some drawbacks of Factor Xa inhibitors include uncertainty about dosing in some patient populations (eg, renal dysfunction, marked extremes of body weight), and their higher drug cost.
{"title":"Factor Xa inhibitors, Era to replace traditional anticoagulants","authors":"S. Chaudhry","doi":"10.18231/j.jpbs.2022.004","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.004","url":null,"abstract":"The past 15 years have seen increased usage of factor Xa inhibitor anticoagulants such as rivaroxaban, apixaban, and edoxaban, along with dabigatran (competitive direct thrombin inhibitor), which have been used increasingly in various clinical settings, for the prevention and treatment of thrombosis. In many ways Factor Xa inhibitors have replaced the use of warfarin, which requires prudent monitoring . Factor Xa inhibitor short half-lives, compared to warfarin’s, provide some assurance that the drug concentrations will decline rapidly when therapy is discontinued in patients with normal renal function. Good haemostatic efficacy was achieved in 83% patients on apixaban and 80% patients on rivaroxaban . Major bleeding events in nonvalvular atrial fibrillation patients on rivaroxaban were 3.6% per year and on apixaban were 2.13% per year in respective landmark trials conducted. Some drawbacks of Factor Xa inhibitors include uncertainty about dosing in some patient populations (eg, renal dysfunction, marked extremes of body weight), and their higher drug cost.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"53 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90083900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-15DOI: 10.18231/j.jpbs.2022.001
F. Tamboli
{"title":"Current trends in pharmaceutical and biological sciences","authors":"F. Tamboli","doi":"10.18231/j.jpbs.2022.001","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.001","url":null,"abstract":"","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76862569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.18231/j.jpbs.2021.014
N. Kolhe, V. Bhaskar, Shubham Ghosh, Sanskruti Kharavtekar, Savni Prabhu, Prathamesh Gangurde, Prachi Navale
A widespread increase in the prevalence of fungal infections has been documented in recent decades. Candida albicans infections, which are frequently refractory and linked with high morbidity and mortality, place a significant burden on public health, despite the fact that existing antifungal medicines are restricted and associated with toxicity. Fungi are one of the most underappreciated killers, as evidenced by the fact that Amphotericin B and other commercially available antifungal therapies are still recognized as gold standards. The majority of commonly used antifungal medications have toxicity, effectiveness, and cost disadvantages. As a result of these limitations, there is a growing demand for the development of a novel antifungal medication treatment that acts selectively on new targets while having the fewest adverse effects. Natural goods, whether as pure phytocompounds or regulated plant extracts, give prospects for the development of lead compounds that may subsequently be turned into diverse synthetic medications with the appropriate alterations. These herbs can also be used as a component of a herbal synthetic combination, lowering the minimum required dose of the synthetic medicine (when taken singly) and reducing the risk of adverse effects. The goal of this research is to reduce the minimum required concentrations of today's antifungal medications by mixing them with a few less well-known herbal extracts while maintaining their efficacy.
{"title":"Studies on the combinations of some herbals with various chemical entities as a potent antifungal agents","authors":"N. Kolhe, V. Bhaskar, Shubham Ghosh, Sanskruti Kharavtekar, Savni Prabhu, Prathamesh Gangurde, Prachi Navale","doi":"10.18231/j.jpbs.2021.014","DOIUrl":"https://doi.org/10.18231/j.jpbs.2021.014","url":null,"abstract":"A widespread increase in the prevalence of fungal infections has been documented in recent decades. Candida albicans infections, which are frequently refractory and linked with high morbidity and mortality, place a significant burden on public health, despite the fact that existing antifungal medicines are restricted and associated with toxicity. Fungi are one of the most underappreciated killers, as evidenced by the fact that Amphotericin B and other commercially available antifungal therapies are still recognized as gold standards. The majority of commonly used antifungal medications have toxicity, effectiveness, and cost disadvantages. As a result of these limitations, there is a growing demand for the development of a novel antifungal medication treatment that acts selectively on new targets while having the fewest adverse effects. Natural goods, whether as pure phytocompounds or regulated plant extracts, give prospects for the development of lead compounds that may subsequently be turned into diverse synthetic medications with the appropriate alterations. These herbs can also be used as a component of a herbal synthetic combination, lowering the minimum required dose of the synthetic medicine (when taken singly) and reducing the risk of adverse effects. The goal of this research is to reduce the minimum required concentrations of today's antifungal medications by mixing them with a few less well-known herbal extracts while maintaining their efficacy.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78075151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：